Mayumi Yamada

Chymase inhibitors may prevent postoperative adhesion formation.

Beneficial effects of cardiac chymase inhibition during the acute phase of myocardial infarction.

Increased local angiotensin II formation in aneurysmal aorta.

Suppression of basic fibroblast growth factor-induced angiogenesis by a specific chymase inhibitor, BCEAB, through the chymase-angiotensin-dependent pathway in hamster sponge granulomas.

Impact of chymase inhibitor on cardiac function and survival after myocardial infarction.

Synaptic adhesion molecule OBCAM; synaptogenesis and dynamic internalization.

Origin of climbing fiber neurons and their developmental dependence on Ptf1a.

IgLON cell adhesion molecule Kilon is a crucial modulator for synapse number in hippocampal neurons.

Impact of mammalian target of rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic hematopoietic cell transplantation.

Raloxifene and stroke risks in Japanese postmenopausal women with osteoporosis on postmarketing surveillance.

Inhibitory and excitatory subtypes of cochlear nucleus neurons are defined by distinct bHLH transcription factors, Ptf1a and Atoh1.

Self-refocused spatial-spectral pulse for positive contrast imaging of cells labeled with SPIO nanoparticles.

Manganese-guided cellular MRI of human embryonic stem cell and human bone marrow stromal cell viability.

Magnetic resonance imaging of human embryonic stem cells.

Positive contrast with alternating repetition time SSFP (PARTS): a fast imaging technique for SPIO-labeled cells.

Two distinct amyloid beta-protein (Abeta) assembly pathways leading to oligomers and fibrils identified by combined fluorescence correlation spectroscopy, morphology, and toxicity analyses.

A molecular MRI probe to detect treatment of cardiac apoptosis in vivo.

Thioredoxin mediates oxidation-dependent phosphorylation of CRMP2 and growth cone collapse.

Lower value of glycated haemoglobin relative to glycaemic control in diabetic patients with end-stage renal disease not on haemodialysis.